Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort StudyDonna R. Rivera, Jeremy L. Warner, Brian I. Rini et al.|Cancer Discovery|2020Cited by 138
Germline variants associated with toxicity to immune checkpoint blockadeStefan Groha, Alexander Gusev, Sarah Abou Alaiwi et al.|Nature Medicine|2022Cited by 106
Cancer Care Disparities during the COVID-19 Pandemic: COVID-19 and Cancer Outcomes StudyAndrew Schmidt, Deborah B. Doroshow, Ziad Bakouny et al.|Cancer Cell|2020Cited by 72
Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes studyZiad Bakouny, Deborah B. Doroshow, C. Labaki et al.|Annals of Oncology|2022Cited by 33
The CoVID‐TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID‐19Ang Li, Rachel Rosovsky, Nicole M. Kuderer et al.|Journal of Thrombosis and Haemostasis|2021Cited by 30